The Ross procedure was associated with a “striking” survival advantage over bioprosthetic aortic valve replacement (AVR) surgery for young and middle-age adults in a propensity-matched analysis.
Over a mean 14.5 years of follow-up among a cohort of consecutive patients getting either procedure, Ross recipients had a hazard ratio of 0.35 for all-cause mortality (95% CI 0.14-0.90) compared with patients who underwent bioprosthetic AVR, with seven (6.5%) versus 21 deaths (19.4%), respectively.
